Academic Journal
Head-to-head comparison of biparametric versus multiparametric MRI of the prostate before robot-assisted transperineal fusion prostate biopsy
| العنوان: | Head-to-head comparison of biparametric versus multiparametric MRI of the prostate before robot-assisted transperineal fusion prostate biopsy |
|---|---|
| المؤلفون: | Thaiss, Wolfgang M., Moser, Simone, Hepp, Tobias, Kruck, Stephan, Rausch, Steffen, Scharpf, Marcus, Nikolaou, Konstantin, Stenzl, Arnulf, Bedke, Jens, Kaufmann, Sascha |
| المساهمون: | Universitätsklinikum Tübingen |
| المصدر: | World Journal of Urology ; volume 40, issue 10, page 2431-2438 ; ISSN 1433-8726 |
| بيانات النشر: | Springer Science and Business Media LLC |
| سنة النشر: | 2022 |
| الوصف: | Purpose Prostate biparametric magnetic resonance imaging (bpMRI) including T2-weighted imaging (T2WI) and diffusion-weighted imaging (DWI) might be an alternative to multiparametric MRI (mpMRI, including dynamic contrast imaging, DCE) to detect and guide targeted biopsy in patients with suspected prostate cancer (PCa). However, there is no upgrading peripheral zone PI-RADS 3 to PI-RADS 4 without DCE in bpMRI. The aim of this study was to evaluate bpMRI against mpMRI in biopsy-naïve men with elevated prostate-specific antigen (PSA) scheduled for robot-assisted-transperineal fusion-prostate biopsy (RA-TB). Methods Retrospective single-center-study of 563 biopsy-naïve men (from 01/2015 to 09/2018, mean PSA 9.7 ± 6.5 ng/mL) with PI-RADSv2.1 conform mpMRI at 3 T before RA-TB. Clinically significant prostate cancer (csPCa) was defined as ISUP grade ≥ 2 in any core. Two experienced readers independently evaluated images according to PI-RADSv2.1 criteria (separate readings for bpMRI and mpMRI sequences, 6-month interval). Reference standard was histology from RA-TB. Results PI-RADS 2 was scored in 5.1% of cases (3.4% cancer/3.4% csPCa), PI-RADS 3 in 16.9% (32.6%/3.2%), PI-RADS 4 in 57.6% (66.1%/58.3%) and PI-RADS 5 in 20.4% of cases (79.1%/74.8%). For mpMRI/bpMRI test comparison, sensitivity was 99.0%/97.1% ( p < 0.001), specificity 47.5%/61.2% ( p < 0.001), PPV 69.5%/75.1% ( p < 0.001) and NPV 97.6%/94.6% (n.s.). csPCa was considered gold standard. 35 cases without cancer were upgraded to PI-RADS 4 (mpMRI) and six PI-RADS 3 cases with csPCa were not upgraded (bpMRI). Conclusion In patients planned for RA-TB with elevated PSA and clinical suspicion for PCa, specificity was higher in bpMRI vs. mpMRI, which could solve constrains regarding time and contrast agent. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1007/s00345-022-04120-1 |
| DOI: | 10.1007/s00345-022-04120-1.pdf |
| DOI: | 10.1007/s00345-022-04120-1/fulltext.html |
| الاتاحة: | http://dx.doi.org/10.1007/s00345-022-04120-1 https://link.springer.com/content/pdf/10.1007/s00345-022-04120-1.pdf https://link.springer.com/article/10.1007/s00345-022-04120-1/fulltext.html |
| Rights: | https://creativecommons.org/licenses/by/4.0 ; https://creativecommons.org/licenses/by/4.0 |
| رقم الانضمام: | edsbas.22DADF49 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1007/s00345-022-04120-1 |
|---|